STOCK TITAN

Evommune CEO Luis C. Pena amends two stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Evommune, Inc. (EVMN) reported that President & CEO Luis C. Pena amended two stock options on November 13, 2026. Each old option was deemed canceled and replaced by an option covering the same number of underlying shares. The replacement option covering 796,841 shares has an exercise price of $7.63 per share, compared with $16.00 for the canceled option; the replacement covering 291,420 shares also has an exercise price of $7.63 per share, compared with $26.77 for the canceled option.

For either replacement option, an exercise before the earliest of November 13, 2027, a Change in Control, or certain specified employment-related events carries a premium exercise price equal to the original exercise price. The 796,841-share option’s first quarter vested on November 5, 2026, with the remainder vesting in 36 equal monthly installments. The 291,420-share option’s first quarter is scheduled to vest on April 16, 2027, followed by 36 equal monthly installments. Vesting is subject to continuous service.

Insider Pena Luis C.
Role President & CEO
Type Security Shares Price Value
Disposition Stock Option (Right to buy) F1, F2, F3 796,841 -- --
Grant/Award Stock Option (Right to buy) F1, F2, F3 796,841 -- --
Disposition Stock Option (Right to buy) F4, F2, F5 291,420 -- --
Grant/Award Stock Option (Right to buy) F4, F2, F5 291,420 -- --
Holdings After Transaction: Stock Option (Right to buy) — 1,088,261 options (Direct)
Holdings Before and After: Stock Option (Right to buy), 1,088,261 to 1,088,261 options (Direct)
Footnotes (5)
  1. F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
  2. F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
  3. F3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
  4. F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
  5. F5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Underlying shares in replacement option 796,841 shares Amended November 13, 2026; exercise price $7.63 per share; canceled option exercise price was $16.00 per share.
Underlying shares in replacement option 291,420 shares Amended November 13, 2026; exercise price $7.63 per share; canceled option exercise price was $26.77 per share.
Replacement-option exercise price $7.63 per share Applies to both replacement options.
First option expiration November 4, 2035 Replacement option covering 796,841 underlying shares.
Second option expiration April 15, 2036 Replacement option covering 291,420 underlying shares.
Option Repricing technical
"a one-time stock option repricing (the "Option Repricing")"
premium exercise price technical
"pay a premium exercise price equal to the original exercise price"
Change in Control technical
"a Change in Control, as defined in the Issuer's 2025 Plan"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Good Reason technical
"resignation following a Change in Control for Good Reason"
continuous service technical
"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option changes did Evommune (EVMN) CEO Luis C. Pena report?

Luis C. Pena, President & CEO, reported the deemed cancellation and replacement of options covering 796,841 and 291,420 underlying shares. Both replacement options have an exercise price of $7.63 per share; the canceled options had exercise prices of $16.00 and $26.77 per share, respectively.

When do Luis C. Pena’s replacement options expire?

The replacement option covering 796,841 shares expires November 4, 2035, and the replacement option covering 291,420 shares expires April 15, 2036.

When can Evommune CEO Luis C. Pena’s repriced options carry a premium exercise price?

If Pena exercises either replacement option before the earliest of November 13, 2027; a Change in Control; or his death or Disability, termination by Evommune without Cause, or resignation following a Change in Control for Good Reason, the premium exercise price equals the original exercise price per share. The 2025 Equity Incentive Plan defines the applicable Change in Control, Disability, and Cause terms; Good Reason is defined in his employment agreement, if applicable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pena Luis C.

(Last)(First)(Middle)
C/O EVOMMUNE, INC.
1891 PAGE MILL ROAD

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1611/13/2026D(1)796,841 (3)11/04/2035Common Stock796,841(2)0.00D
Stock Option (Right to buy)$7.6311/13/2026A(1)796,841 (3)11/04/2035Common Stock796,841(2)796,841D
Stock Option (Right to buy)$26.7711/13/2026D(4)291,420 (5)04/15/2036Common Stock291,420(2)0.00D
Stock Option (Right to buy)$7.6311/13/2026A(4)291,420 (5)04/15/2036Common Stock291,420(2)291,420D
Explanation of Responses:
1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Remarks:
/s/ Gregory S. Moss, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading